{"id":"NCT00851318","sponsor":"Astellas Pharma Inc","briefTitle":"Long-term Treatment Study of Certolizumab Pegol (CDP870) as Add-on Medication to Methotrexate in Japanese Rheumatoid Arthritis (RA) Patients","officialTitle":"A Multicenter, Open-label, Long-term Safety Study of CDP870 to Evaluate the Safety and Efficacy of CDP870 Administered in Combination With Methotrexate (MTX) Over the Long Term in Patients With Active Rheumatoid Arthritis Transferred From the Efficacy Confirmatory Study (Study 275-08-001)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-03","primaryCompletion":"2013-06","completion":"2013-06","firstPosted":"2009-02-25","resultsPosted":"2014-09-17","lastUpdate":"2014-11-03"},"enrollment":285,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"Certolizumab pegol","otherNames":["CDP870","Cimzia"]},{"type":"DRUG","name":"Methotrexate","otherNames":[]}],"arms":[{"label":"Certolizumab pegol 200 mg","type":"EXPERIMENTAL"},{"label":"Certolizumab pegol 400 mg","type":"EXPERIMENTAL"}],"summary":"The objectives of this study are to evaluate the safety and efficacy of certolizumab pegol as add-on medication to methotrexate over the long term in Japanese RA patients transferred from Study 275-08-001 (NCT00791999), and to evaluate the effects of different dosing regimens on the safety and efficacy of certolizumab pegol in American College of Rheumatology 20% (ACR20) responders who completed Study 275-08-001.","primaryOutcome":{"measure":"Number of Participants With Adverse Events","timeFrame":"From the first dosing of this study up to 12 weeks (84 days) after the last dosing. The dosing was allowed until launch of certolizumab pegol for RA in Japan. The maximum duration on study drug was 204 weeks.","effectByArm":[{"arm":"Discontinued Non-responders 200 mg","deltaMin":77,"sd":null},{"arm":"Completed Non-responders 200 mg","deltaMin":18,"sd":null},{"arm":"Completed Responders 200 mg","deltaMin":92,"sd":null},{"arm":"Completed Responders 400 mg","deltaMin":90,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":6},"locations":{"siteCount":8,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":21,"n":81},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Pharyngitis","Eczema","Bronchitis"]}}